RETATRUTIDE 20mg - (w/o water)

Retatrutide 20mg: The Triple-Action Metabolic Catalyst

Comes without solvent. You can get bacteriostatic water in many places, for example, HERE

​ Unleash the next generation of metabolic and weight management support with Retatrutide (LY-3437943).

​ Retatrutide is an investigational triple-receptor agonist designed to provide a comprehensive approach to managing body weight and supporting metabolic health. Currently in late-stage clinical trials, this peptide has demonstrated groundbreaking potential, significantly exceeding the weight loss results of previous-generation medications in studies.

​ Basic Knowledge: How it Works (Triple-Action Mechanism)

​Retatrutide is unique because it is a triple agonist, meaning it activates three key hormone receptors in the body simultaneously:

​GLP-1 (Glucagon-Like Peptide-1): Promotes a feeling of fullness (satiety), slows stomach emptying, and helps regulate blood sugar by boosting insulin release.

​GIP (Glucose-Dependent Insulinotropic Polypeptide): Works with GLP-1 to enhance insulin secretion and is involved in metabolism and fat breakdown.

​Glucagon (GCG): This receptor activation is key, as it is theorized to increase energy expenditure (calorie burning) and promote the breakdown and utilization of stored fat.

​ By combining these three pathways, Retatrutide offers a powerful, multi-pronged strategy to reduce appetite, control blood sugar, and enhance fat loss.

​ Dosage and Administration (Based on Clinical Trial Protocols)

​Please note: Retatrutide is not yet an FDA/EMA-approved medication, and a standard dosing schedule has not been officially established. Clinical trials utilize a gradual titration schedule to enhance tolerability and minimize side effects.

​

Product Strength: Retatrutide 20mg (Lyophilized Powder)

​ Administration: Typically administered as a once-weekly subcutaneous (under the skin) injection.

​ Starting Dose: In trials, participants generally begin at a lower dose (e.g., 1mg or 2mg weekly).

​ Titration: The dose is progressively increased every 4 weeks (e.g., to 4mg, then 8mg, and then the higher maintenance doses) to allow the body to adjust.

​

20mg Note: The 20mg quantity represents the total active ingredient in the vial, which, after reconstitution, allows for multiple doses based on the specific weekly regimen followed. Higher doses in clinical trials have generally ranged up to a maximum of 12mg weekly. Consultation with a qualified healthcare professional is essential for determining a safe and effective dosing schedule.

​
Potential Side Effects (Based on Clinical Trials)

​ As a powerful incretin mimetic, Retatrutide's effects on the gastrointestinal (GI) system are the most common side effects reported in clinical studies. These are typically mild-to-moderate and tend to decrease as the body adjusts to the medication, especially when following a proper titration schedule.

​ Common Side Effects:

​ Gastrointestinal Distress: Nausea, vomiting, diarrhea, and constipation.

​ Other: Some participants reported dose-dependent increases in heart rate, particularly during the first few weeks of treatment.

​Important Considerations:

​ Dosage-Dependent Effects: Higher doses were associated with a higher incidence and severity of GI side effects in clinical research.

​ Thyroid Tumors: Similar to other medications in this class, there is a theoretical risk of thyroid C-cell tumors (medullary thyroid carcinoma) based on animal studies.

​ Disclaimer: This product is sold for research purposes only and is not intended for human consumption. The information provided is based on public clinical trial data and is not a substitute for professional medical advice.

​